Anti-neutrophil cytoplasmic antibodies-associated vasculitides (AAVs) are a heterogenous group of inflammatory diseases which primarily involve small vessels and include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). They present heterogeneous clinical manifestations, while their diagnosis and management still remain a challenge for clinicians. Nowadays, the treatment is based on two different regimens: the remission-induction treatment and the remission-maintenance treatment. The therapeutic armamentarium has grown over the years, with the aim to lessen adverse effects, improve quality of life of patients and maintain the disease under control. Biological treatments are the future: they act on different pathogenic pathways and may offer in the future a personalized management approach tailored to actual clinical manifestations. The latest guidelines were published in 2015 by the European League Against Rheumatism (EULAR) and still represent the vade mecum for the management of AAVs. In this review, we will focus on the principal strategies to treatAAVs. We discuss the remission-induction therapy and the remission-maintenance therapy; we have also distinguished the management of GPA and MPA from that of EGPA, because of their different clinical pictures

EULAR guidelines on ANCA-associated vasculitis in the real life / Marvisi, Chiara; Galli, Elena; Manzini, Carlo Umberto; Sandri, Gilda; Salvarani, Carlo. - In: BEYOND RHEUMATOLOGY. - ISSN 2612-5110. - 2:3(2021), pp. 1-5. [10.4081/br.2020.50]

EULAR guidelines on ANCA-associated vasculitis in the real life

Marvisi, Chiara;Galli, Elena;Sandri, Gilda;Salvarani, Carlo
2021

Abstract

Anti-neutrophil cytoplasmic antibodies-associated vasculitides (AAVs) are a heterogenous group of inflammatory diseases which primarily involve small vessels and include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). They present heterogeneous clinical manifestations, while their diagnosis and management still remain a challenge for clinicians. Nowadays, the treatment is based on two different regimens: the remission-induction treatment and the remission-maintenance treatment. The therapeutic armamentarium has grown over the years, with the aim to lessen adverse effects, improve quality of life of patients and maintain the disease under control. Biological treatments are the future: they act on different pathogenic pathways and may offer in the future a personalized management approach tailored to actual clinical manifestations. The latest guidelines were published in 2015 by the European League Against Rheumatism (EULAR) and still represent the vade mecum for the management of AAVs. In this review, we will focus on the principal strategies to treatAAVs. We discuss the remission-induction therapy and the remission-maintenance therapy; we have also distinguished the management of GPA and MPA from that of EGPA, because of their different clinical pictures
2021
2021
2
3
1
5
EULAR guidelines on ANCA-associated vasculitis in the real life / Marvisi, Chiara; Galli, Elena; Manzini, Carlo Umberto; Sandri, Gilda; Salvarani, Carlo. - In: BEYOND RHEUMATOLOGY. - ISSN 2612-5110. - 2:3(2021), pp. 1-5. [10.4081/br.2020.50]
Marvisi, Chiara; Galli, Elena; Manzini, Carlo Umberto; Sandri, Gilda; Salvarani, Carlo
File in questo prodotto:
File Dimensione Formato  
br-2-3-50.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 649.05 kB
Formato Adobe PDF
649.05 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1278569
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact